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Angioplaaty: Clinical and Economic Implications
W.S. Weintraub, S.J. Boccuzzi, Y. Shen, Z. Ghszzal, J.S. Douglas, Jr.,
D.C. Morris, S.B. King Ill. Emory University Atlanta, GA, USA
It is the purpose of this study to identify patients at high risk of acute close or
other events after PTCAwho could benefit from GPllbllla blockade, thrombin
inhibition or other therapy to inhibit thrombus formation. In this study 5946
patienta had procedures to 7591 sitaa between 1/1/93 and 12/31/95. There
were 98(l.23%) episodes of acute closure inthelaboratoty. Hospitalmortality
was 0.6Y0without acute closure and 6.9% with acute closure. There were
only trends for clinical variables predicting acute closure: hypertension (p
= 0.062), and ejection fraction (p = 0.094). Several lesion characteristiee
predicted acute closure including length (p= 0.031), diameter stermsis pre-
proeedure (p = 0.015), ulcer (p = 0.036), diffuse disease (p = 0.073), calcium
(p = 0.0005), branch point (p = 0.005) and thrombus (p < 0.00Q1). The
multivariate correlates of acute closure were leaion length (OR 1.021 par
mm), thrombus (OR 1.955),Calcium(OR 2.241) and branch point (OR 1.790).
59% of patients had < 1% probability of acute closure. Similar models were
built foreomposite endpoints. There were 211 events of the composite acute
cloeure in the Iaksxatory, death or myoeardial infarction. The multivariate
predictors were lesion length (OR 1.028 par mm), thrombus (OR 2.73) and
calcium (OR 2.37). The 150 patients with the composite endpoint had a
29% chance of requiring CABG vs 1.7% in 5654 without the eompoeite
endpoint. Hospital cost in the composite endpoint patients was $24,789 vs
$10,202 without the composite endpoint. A similar model included CABG in
the composite endpoint with similar correlates. This permitted the creation of
a high risk profile of 24% of sites with a risk of=- 3% and which included 469!.
of events. Inhibition of thrombus ean be targeted to a high riak population
using simple anatomic criteria, permitting rational and cost effective patient
selection.
m108210 What Predicts Contrast Nephropathy AfterCoronary Intervention? Inaighte from the IMPACT
II Trial
M.C. Thel, C.J. Davideon, F.V.Aguirre, S.L. Peek, J.E. Tcheng, A.M. Lincdf,
E.J. Topol, R.M. Califf for the IMPACT II Investigators. Duke University
Medical Centec Durham, NC, USA
To determine the factors associated with ecmtrestnephropathy (CN) after
percutaneous Ooronav intervention, we analyzed the 4010 patients enrolled
in IMPACT-II. CN was defined as an increase in serum creatinine (Cr) after
contrast administration by z 0.5 m~dL. The median baseline Cr was 1
(0.9, 1.2); the median change in Cr following intervention was O(-0.1, 0.1).
Overall, 88 patiente (2%) developed CN and 9 patients required dialysis.
The variables included in the multiple l~istic regression model and their
associations are listed in the table:
Variable x’ p
Baseline Cr 15.s4 0.0003
Age 8.50 0.0035
Ejectionfraction 5.30 0.0213
Contrestvolume 4.25 0.0393
Diabstes meilitus(2 df) 4.58 0.1015
rXntrastclass (ioniolnonionicham) 0.66 0.4148
Calcium arrtagonistpre-prwedure 0.02 0.8751
Hypertension 0.01 0.9147
Total 33.96 0,0001
Baseline renal insufficiency is the most significant risk factor for CN
after coronary intervention. Diabetes, hypertension, contrast class, and pre-
treatment with calcium antagonists were not predictive.
D108211 Differential Effacta of Argatroban and Heparin on
Hemochron and HemoTec Activated Clotting
Timaa in Patients Undergoing Coronary
Intervantional Procedures
M.J. Hursting, J.-C. Becker, B.E. Lewis, O. Iqbal, J.M. Walenga,
J.J. Ferguson. TexasBiotechnology Corp., and The TexasHaart Institute,
Houston, TX, USA
Anticoagulation during coronary interventional procedures (1P)is often mon-
itored using the whole blcsxl activated clotting time (ACT). We sought to
establish the differential effects of the direct thrombin inhibitor argatroban,
compared to heparin, on Hemoehron ACTS using celite activator versus
HemoTec ACTSusing kaolin activator in patients undergoing 1P.Paired, si-
multaneous ACT values were determined using both methods for (a) 75
specimens from nine patients undergoing IP with argatroban anticoagula-
tion, and (b) 36 spaeimens from five patients undergoing IP with heparin
anticoagulation. By least squares regression analyses (Fig. 1), paired ACT
values were strongly correlated (r ? 0.86) for both druga. However, arga-
troban prolonged HemoTec and Hemochron ACTS equally (slope = 0.98
+ 0.06), whereas heparin prolonged HemoTae ACTS less than Hemoehron
ACTS(slope = 0.68+ 0.07; shown in Fig. 1).
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Cone/usiorrs:Argatrobanandheparin exert dissimilar effaetson Hemochron
and HemoTecAC.TSin patients undergoing 1P.Caution should thus be taken
if applying target ACT values recommended for adequate hepannization to
interventional procedures using argatroban.
\ 1082-12 I AdditionaiHeparin hIcraaseathe ACT and
Reducas the Likelihood of Abrupt Closura During
PTCA
J.A. Bittl, A.P. Selwyn, R.N. Piana, W.H. Ahmed. Brigham & Women’s
Hospital, Boston, MA, USA
The Hirulog Angioplasty Study allowed examination of the relation betwean
the risk of abrupt vessel closure (AVC) and activated clotting timea (ACT)
during PTCA. In uneventful, brief procedures the risk of AVC was inversely
related to the ACT achieved on heparin (OR= –1 .6’%0per IO-SW increase in
ACT [95% Cl = –3.4Y0,0.2%], P= 0.08, see below). The effect of additional
heparin given during complicated, prolonged procedures has not been de-
fined. Again, the risk of AVC was inversely related to the maximal ACT (OH
= –1,1% [95% Cl –2.3%, –0.1%], P= 0.04):
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Abrupt vessel closure is an adverse event that is strongly related to bad
outcomes after PTCA. This study suggests that increasing the ACT with
additional heparin reduces the risk of abrupt closure even in prolongad and
complicated procedures.
Wednesday, March 19, 1997, 3:00 p.m.–5:OOpm,
Anaheim Convention Center, Hall E
Presentation Hour: 4:00 p.m.–5:OOp.m.
I 1083-116I AntiorridantaAttenuate NOrepinephrine-hIdLIced
Cardiac Sympathetic Nerve Dysfunction
N.K. Rounds, S.Y. Felten, CS. Liang. University of Rochester Medica/
Cantec Rochestec N% USA
Cardiac norepinephrine (NE) uptake activity and noradrenergic nerve pro-
files are reduced in animals with congestive heart failure (CHF) or chronic
NE infusion. We hypothesized this sympathetic dysfunction is caused by
bcal accumulation of NE-derived oxidative products. To determine whether
these changes could be prevented by antioxidant, we administered vita-
mins (vits) A, C, and E or placebos to ferrets treated with NE (1.3 mgld)
or control pellats for 4 weeks (n = 6-10 per group). NE infusion caused
a 4-5 fold increase in plasma NE, but had no significant effect on bleed
pressure or heart rate. We measured plasma NE (rig/ml) and left ventricular
(LV) NE uptake activity (fmol/mg/15 rein). LV sympathetic nerve terminal Dro-
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files were quantified using glyoxylic acid (SPG)-inducad histofluorescence
and immunohlstochemical staining of neuropeptide Y (NPY), a sympathetic
neurotransmitter which is co-released with NE.
Control Norepinephrirre
Vlts Placebo Vits Placebo
Plasma NE 0.3s i 0.09 0.50 * 0.05 1,78 & 0.28 2,08 + 0,46
NE uptake 64.9* 6.7 65.0 + 7.6 57.6 k 6.2 43.1 & 5,2++
SPG 137.8 l 11.9 140.3 + 10.1 125.5 + 12.1 S8.4+ &4*+
NPY 87.9 & 6.8 99,3 k4,3 t02.6+ 7.4 45.9+3.1”+
(*Ps 0.05 versus controlgroup;‘ps 0.05 versus NE+vits group)
Antioxidant attenuated the decrease in cardiac NE uptake activity and
loss of sympathetic naurotransmitters caused by excess NE. These findings
implicate NEderivad oxygen free radicals in cardiac noradrenergic dysfunc-
tion and thus, suggest a potentially therapeutic role for antioxidant vitamins
In CHF.
1083-117 TheEndogenousNatriureticPeptldeSystem
ModulatesDiastolicFunctionin Experimental
HeartFailure
Kazuhiro Yamamoto, John C. Burnett Jr., Margaret M. Radfield. Mayo
Clinic, Rochester, MN, USA
Atrial and brain natriuretic peptides (of myocyte origin) and C-type natriuretic
peptides (of endothelial origin) are vasoactive peptides whosa production
by the heart is enhanced In heart failure (HF). Natriuretic peptide (NP)
receptors have beendemonstratedonLV myocytes and in-vitro studies have
suggested that cGMP,the NP second mesaenger, hes effects on myocardial
function. Therefore, we hypothesized that the endogenous NP system acts
as an autocrine/paractfne system to modulate LV function in HF. To test this
hypothesis, HS-142-1 (HS), a apecific antagonist of the NP receptors, was
infused into the coronary arteries in 5 dogawith chronic HF produced by rapid
ventricular pacing at doaee dasignad to produce selective blockade of the
intracardiac NP system without systemic effects. Heart rate was controlled
by atrial pacing during the infusion. The time constant of LV relaxation (Tau),
the time to the onset of LV relaxation (t), mean aortic pressure (mAoP), LV
end-diastolic pressure (LVEDP)and peak+ dP/dt were measured (*ps 0.05
vs Control, ‘ps 0.05 vs HS dose 1)
Control HS doss 1 HS dose2
mAoP (mmHg) 76+ 6 79& 7 63 k 10
LVEDP (mmHa) 15+6 16+S 17+6
Peak & dP/dt &mH@) 1147 * 212 1199 + 238 1202 * 244
Tau (ins) 39* 7 45* 7’ 49 *8**
t (ins) 22s * 12 238 & 15” 243* 16*
Antagonism of the intracardiac NP system in HF prolonged t and Tau
without effects on loading conditions or inotropic function.
Conckrsions: In HF, the activated endogenous NP syatem functions in
the heart as an autocrine/paracrine system to enhance LV diastolic function
by accelerating LV relaxation These data indicate that the NP system is an
important bcal regulator of cardiac function in HF.
1083-118 TheSynergisticEffectsof VitaminE and
SeleniumonCardiecAntioxidantLevelsine
Modelof IronOverloedCardiomyopathy
W.J. Bartfay, F. Dawood, W.-H. Wen, E. Barffay, M.J. Sole, N. Oliviari,
P.Backx, P.Liu. The TorontoHospital, Center for CVReaearch, University
of Toronto, Toronto, Canada
Iron overtoed cardiomyopathy is a prototype of restrictive cardiomyopathy,
and is a common cauaa of heati failure in young patients worldwide. Oxygen
free radical (OFR) production may be pathogenic in heari failure of diverse
etiology, including iron overload cardiomyopathy. The myocardium has sev-
ersl intrinsic antioxidants to defend againstfraa radicals, including glutathione
peroxidase (GPx), selenium (Sa) and vitamin E (Vit E). The deficiancias of
the Iatter?spacias are known to cause heart failure. Redetermined whether
chronic supplementation of Vit E and Se can improve myocardial antioxidant
defenses inamodel of iron overload cardiomyopathy. Ironovarioad state was
created in B6D2FI mice by iron dextran injection (5 mg i.p.) daily for4 weeks.
The animals were simultaneously randomized to receive Vit E (a-tocopherol
40 mg i.p.) or Sa (aOdiumselenita 1 ppm P.o.) supplementation individually
or both togethar (Vit E+Se) for 4 weeks (n = 20), vs. DIOW p.o. as controla
(n= 5). The hearts were harvested for determination of GPx (pmol/L) and
SE levels (nmol/L). All data presented as maan + SD:
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Control Vlt E Se Vit E + Se
GPx 162 + 9S 152 +72 175 +66 346 + 126**
Se 87*26 96+31 775 *74 725 h 968*”
“p <0.001 comparedto controlor individualVit E & Se groups.
We corrclude that vitamin E and selenium may function synergistically
in the myooardium to provide important antioxidant defense mechanisms
againat free radical damage, such as found in Iron overload and hean failure.
These elements may also have therapeutic implications in theae renditions.
11083-1191AngloganlcFactorsBasicFNwoblastGI’owth
FactorandAngiogenininAdvancedHeart
FailurePatients
D.M. Farrnakis, P.D.Papedopouloa, E.V. Economou, M.G. Toutouza,
K.1.Kapetanios, D.P.Papedopoulos, T.A. Argiriou, P.K.Toutouzas.
Cardiology Clinic, University of Athens, Hippokration Hoapit8/,Athens,
Greece
There are rrtanydatawhich suppoflthat in advanced heart failure (HF)occurs
neovascularisation and hyperplaaia of cardiac myocyfes both disproportion-
ate to the hyperfrophy. Basic Fibroblast Growth Factor (bFGF), a multifunc-
tional polypeptide which has been localised to adult cardiac myocytes in vitro,
haa angiogenic properties and stimulate proliferation of cardiac myocytes,
endothelial cells etc. Angiogenin (ANG), a non glycosylated polypeptide, so
named for its strong ability to induce new blood vessel growth,but its pre-
cise role in heart diseaseshas not yet been well clarified. The aim of our
study was to investigate any possible role of bFGF and ANG in patients with
heart failure. We studied 50 patients with HF, 41 men, mean age 60 years,
and 9 women, mean age 66 years, of different aetiology - cororra~ hearl
disease (CHD) 2W50, dilated cardiomyopathy(DCM) 11/50, valvulopathy
(VHD) 14/51-, and all classes of NYHA (Class I 8/50, Class II 6150,Class Ill
14/50, Class IV 22/50) and compared to 21 healthy controls (17 men and 4
women age-matched). Patients with acute or chronic inflammatory disease,
malignancies, collagen disease, thyroid, renal or liver diseaae, hypertension
or diabetes mellitua have been excluded from our study. Before sampling pa-
tients were clinically ateble and off medication, except diuretica, for a period
of 5 days. Samplas wara maaaured by relevant ELISA kits. For the statistical
analysia t-test for unpaired differences (p) was uaed. Results expressed as
mean values + SEM:
Controls Classes Class Class Class class DCM VHD CHD
I-W I II Ill Iv
bFGF 1.95+ 5.69+ 3.14+ 3.74* 4.17+ 8,09+ 4.56+ 4.76* 7.57*
(pg/ml) 0.3S 0.79” 0.92 1.65 1.4* 1.32* 1.13* 1,22* 1,46*
ANG 249.8+ 325.0+ 237* 297.8A 319.2+ 335,4& 320.3* 311.6+ 336.6zt
(rig/ml) 11.6 14.2” 21.2 34.6 23.6* 20,s” 27* 20.2” 23.8”
*p c 0.05 comparedwithcontrols
In conclusion, in end-staga HF patients there is a statistically significant
increase in plasma levels of angiogenic factors bFGF and angiogenin. The
progressive increase of plasma levels of bFGF and ANG suggest a dynamic
continuous process poasibly in naovascularisation. The clinical implication of
this phenomenon in congestive HF needs further investigation.
11083-12OI CachexiainChronicHeartFailure:Leptin
MediatedAnorexiaor CytokineandHormone
Action?
S.D. Ankerl, K.R. Egerer2, M,M. Teixeiral, P.G.Hellewell 1,
P.Ponikowski 1, P.A. Poole-Wilaon1,W.J. KOX2,A.J.S. Coats 1.1 NHL/,
London, UK, 2Dept of Anaasthesio/ogy Charite Berfin, FRG, Germany
The oeuea of cardiac cachexia is not clear. Tha peptida laptin playe a role
in obesity (Ieptin resistance), but alao in weight loss during infaction (Ieptin
overexpression due to TNF-a and endotoxin action, subsequently anorexia).
We aimed to relate body composition changaa (dual x-ray absorptiometry,
lean and fat tissue in relation to haight) to cytokine, hormone, Ieptin, and
soluble [s] CD14 levels (indicative of LPS cell interaction) in 46 CHF patients
(age61 +2y, LVEF26 + 2%, NYHAclass 2.7 + 0.1) and 21 healthy controls
(57 + 2y, p = 0.15). Leptin (p < 0.02), noradrenalina [NA], sTNF receptor 1,
IL-6, sCD14 (all p < 0.004) and insulin (p < 0.03) were increased in CHF.
Nineteen patients were oechectic ([c] dry weight loss 12 + 2 kg over z 6
months, particularly increaead TNFxz, sTNF-RI, sCD14, and NA).
